The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | T-cell lineage mixed chimerism as a prognostic factor in acute leukemia & MDS after allo-HSCT
Vipul Sheth, PhD, Fred Hutchinson Cancer Research Center, Seattle, USA, discusses the findings of a single center retrospective study of T-cell lineage mixed chimerism as a prognostic factor in acute leukemias and myelodysplastic syndromes (MDS). T-cell depletion, in particular with alemtuzumab, reduces the risk of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) with unrelated donor peripheral stem cell grafts. However, it has also been associated with an increased occurrence of mixed T-cell chimerism and subsequent relapse. Dr Sheth describes the findings of a study which compared the long-term outcomes of 106 patients with T-cell mixed chimerism to 111 patients with complete chimerism. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
